| Sign In to gain access to subscriptions and/or personal tools. |
Drug-eluting stent thrombosis
Cardiovascular Research, Physiology Institute, University of
Zürich and Cardiology, Cardiovascular Center, University Hospital
Zürich, and Zürich Center for Integrative Human Physiology
(ZIHP), University of Zurich
* To whom correspondence should be addressed.
Stent thrombosis is a rare complication following stent implantation; if it occurs, however, it is associated with a high morbidity and mortality. Despite reduced rates of restenosis, drug-eluting stents (DES) have not reduced the incidence of stent thrombosis as compared with bare-metal stents (BMS). Patient-, lesion-, and procedure-related factors as well as thrombogenicity of the stent itself are involved in the pathogenesis of stent thrombosis. Furthermore, early cessation of dual antiplatelet therapy correlates with an increased risk of stent thrombosis. This review focuses on clinical evidence and pathophysiological mechanisms of stent thrombosis with DES, particularly highlighting prothrombotic effects of the stent itself. Key Words: acute coronary syndrome, drug-eluting stent, stent thrombosis, re-endothelialization,, tissue factor
First published on September 18, 2008, doi:10.1177/1753944708096280 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||